XML 21 R33.htm IDEA: XBRL DOCUMENT
v3.2.0.727

Note 12 - Segment Information (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2015
Notes Tables |
Schedule of Segment Reporting Information, by Segment [Table Text Block] |
|  | Year Ended June 30, |
|  | 2015 |  |  | 20 14 |  |  | 20 13 |
External sales |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 325,897 |  |  | $ | 300,578 |  |  | $ | 288,156 |
Clinical Controls |  |  | 60,377 |  |  |  | 57,185 |  |  |  | 22,419 |
Protein Platforms |  |  | 66,247 |  |  |  | 0 |  |  |  | 0 |
Inter segment |  |  | (273 | ) |  |  | 0 |  |  |  | 0 |
Consolidated net sales |  | $ | 452,246 |  |  | $ | 357,763 |  |  | $ | 310,575 |
|  | Year Ended June 30, |
|  | 2015 |  |  | 20 14 |  |  | 20 13 |
Operating Income |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 171,059 |  |  | $ | 168,041 |  |  | $ | 164,886 |
Clinical Controls |  |  | 18,148 |  |  |  | 17,556 |  |  |  | 8,746 |
Protein Platforms |  |  | 4,469 |  |  |  | 0 |  |  |  | 0 |
Segment operating income |  |  | 193,675 |  |  |  | 185,597 |  |  |  | 173,632 |
Costs recognized upon sale of acquired inventory |  |  | (6,958 | ) |  |  | (7,480 | ) |  |  | (4,501 | )
Amortization of intangibles |  |  | (26,169 | ) |  |  | (10,276 | ) |  |  | (5,061 | )
Acquisition related expenses |  |  | (4,519 | ) |  |  | (2,247 | ) |  |  | (607 | )
Corporate general, selling and administrative expenses |  |  | (9,007 | ) |  |  | (5,845 | ) |  |  | (4,994 | )
Consolidated operating income |  | $ | 147,022 |  |  | $ | 159,750 |  |  | $ | 158,469 |
Goodwill |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 119,450 |  |  | $ | 95,124 |  |  | $ | 84,336 |
Clinical Controls |  |  | 56,349 |  |  |  | 56,349 |  |  |  | 0 |
Protein Platforms |  |  | 214,839 |  |  |  | 0 |  |  |  | 0 |
Consolidated goodwill |  | $ | 390,638 |  |  | $ | 151,473 |  |  | $ | 84,336 |
Intangible assets, net |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 68,777 |  |  | $ | 53,778 |  |  | $ | 40,552 |
Clinical Controls |  |  | 49,130 |  |  |  | 54,998 |  |  |  | 0 |
Protein Platforms |  |  | 174,932 |  |  |  | 0 |  |  |  | 0 |
Consolidated intangible assets, net |  | $ | 292,839 |  |  | $ | 108,776 |  |  | $ | 40,552 |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 439,377 |  |  | $ | 685,302 |  |  | $ | 580,085 |
Clinical Controls |  |  | 66,101 |  |  |  | 55,615 |  |  |  | 24,887 |
Protein Platforms |  |  | 444,899 |  |  |  | 0 |  |  |  | 0 |
Segment assets |  |  | 950,378 |  |  |  | 740,917 |  |  |  | 604,972 |
Corporate cash and available- for- sale investments |  |  | 52,800 |  |  |  | 60,142 |  |  |  | 108,504 |
Corporate property and equipment |  |  | 58,270 |  |  |  | 60,350 |  |  |  | 61,296 |
Corporate, other |  |  | 1,912 |  |  |  | 1,082 |  |  |  | 3,326 |
Consolidated assets |  | $ | 1,063,360 |  |  | $ | 862,491 |  |  | $ | 778,098 |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 13,820 |  |  | $ | 10,879 |  |  | $ | 10,781 |
Clinical Controls |  |  | 7,963 |  |  |  | 7,205 |  |  |  | 389 |
Protein Platforms |  |  | 13,364 |  |  |  | 0 |  |  |  | 0 |
Segment depreciation and amortization |  |  | 35,147 |  |  |  | 18,084 |  |  |  | 11,170 |
Corporate |  |  | 2,079 |  |  |  | 1,091 |  |  |  | 1,151 |
Consolidated depreciation and amortization |  | $ | 37,226 |  |  | $ | 19,175 |  |  | $ | 12,321 |
Capital purchases |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 9,794 |  |  | $ | 4,157 |  |  | $ | 3,248 |
Clinical Controls |  |  | 1,932 |  |  |  | 5,687 |  |  |  | 6,914 |
Protein Platforms |  |  | 8,179 |  |  |  |  |  |  |  |  |
Segment capital purchases |  |  | 19,905 |  |  |  | 9,844 |  |  |  | 10,162 |
Corporate |  |  | 0 |  |  |  | 3,977 |  |  |  | 12,292 |
Consolidated capital purchases |  | $ | 19,905 |  |  | $ | 13,821 |  |  | $ | 22,454 |
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] |
|  | Year Ended June 30, |  |
|  | 2015 |  |  | 20 14 |  |  | 20 13 |  |
External sales |  |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 245,217 |  |  | $ | 190,359 |  |  | $ | 164,308 |  |
Europe |  |  | 134,077 |  |  |  | 97,157 |  |  |  | 88,297 |  |
China |  |  | 26,105 |  |  |  | 18,878 |  |  |  | 14,106 |  |
Other Asia |  |  | 23,806 |  |  |  | 32,704 |  |  |  | 28,608 |  |
Rest of world |  |  | 23,041 |  |  |  | 18,665 |  |  |  | 15,256 |  |
Total external sales |  | $ | 452,246 |  |  | $ | 357,763 |  |  | $ | 310,575 |  |
Long-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |
United States and Canada |  | $ | 119,075 |  |  | $ | 109,790 |  |  | $ | 103,541 |  |
Europe |  |  | 11,239 |  |  |  | 8,340 |  |  |  | 7,129 |  |
China |  |  | 1,286 |  |  |  | 678 |  |  |  | 117 |  |
Total long-lived assets |  | $ | 131,600 |  |  | $ | 118,808 |  |  | $ | 110,787 |  |

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration